$495K
+$495K this year1 filing since 2026 · latest Equity filed
Petragen is a Yale-founded precision therapeutics company in Davie, Florida developing small-molecule treatments for diseases of abnormal mineralization. Its approach intervenes at the physical site where pathological mineralization occurs rather than at a distant signaling target. Named programs span periodontal disease, hypophosphatasia, and calcium pyrophosphate deposition disease. The company was co-founded by Yale pathologist Demetrios Braddock, MD, PhD, who serves as chief scientific officer, with David Kolb as CEO and president.
What sets it apart
Targets the physical chemistry of pathological mineralization directly, and pursues orally available small molecules as alternatives to enzyme-replacement biologics that can cost up to $2 million per year and require near-daily injections.
A preclinical therapeutic platform of small molecules that act at the point where abnormal mineralization occurs, applied across several bone, joint, and dental indications.
